Han Yueting, Zhang Haiyang, Zhou Zhengyang, Liu Rui, Liu Dongying, Bai Ming, Fan Qian, Li Jialu, Zhu Kegan, Li Hongli, Ning Tao, Ying Guoguang, Ba Yi
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China.
Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, 200001, People's Republic of China.
Int J Gen Med. 2021 Apr 1;14:1185-1195. doi: 10.2147/IJGM.S297371. eCollection 2021.
Biliary tract cancers (BTCs) are aggressive malignancies with difficult early diagnosis and poor prognosis. Studies have shown that microRNAs (miRNAs) are expected to be biomarkers of the disease, which indicates that we can diagnose cancers according to the miRNAs that have significant changes. The aim of this study was to explore miRNA biomarkers of BTCs.
A total of 163 samples were collected and divided into the control group, the benign group and the malignant group. High-throughput low-density chips were used to screen miRNAs with significant changes. Then, the preliminary screening test and the verification test were performed by quantitative real time PCR (qRT-PCR). Finally, the level of miRNAs in serum exosomes was measured.
MiR-10a, miR-21, miR-135b, miR-221, and miR-214 were upregulated in the BTCs group compared to the control group. The change in the miR-221 level was statistically significant when the malignant group was compared with the benign group (P<0.01). Meanwhile, miR-135b and miR-214 were enriched in serum exosomes.
Five miRNAs in the serum were found to be significantly upregulated in patients with BTCs. Among them, miR-221 can serve as an early diagnostic marker for BTCs patients. MiR-10a, miR-21, miR-135b and miR-214 can be used as biomarkers for the diagnosis of biliary diseases.
胆道癌（BTCs）是侵袭性恶性肿瘤，早期诊断困难且预后较差。研究表明，微小RNA（miRNAs）有望成为该疾病的生物标志物，这意味着我们可以根据发生显著变化的miRNAs来诊断癌症。本研究的目的是探索BTCs的miRNA生物标志物。
共收集163份样本，分为对照组、良性组和恶性组。使用高通量低密度芯片筛选发生显著变化的miRNAs。然后，通过定量实时聚合酶链反应（qRT-PCR）进行初步筛选试验和验证试验。最后，检测血清外泌体中miRNAs的水平。
与对照组相比，BTCs组中miR-10a、miR-21、miR-135b、miR-221和miR-214上调。恶性组与良性组比较时，miR-221水平的变化具有统计学意义（P<0.01）。同时，miR-135b和miR-214在血清外泌体中富集。
发现血清中的5种miRNAs在BTCs患者中显著上调。其中，miR-221可作为BTCs患者的早期诊断标志物。miR-10a、miR-2
